STUDY OF FOLFIRI + PANITUMUMAB USING ULTRA-SELECTION TECHNOLOGY OF PATIENTS WITH STAGE IV COLORECTAL CANCER REFRACTORY TO IRINOTECAN WITHOUT ANY MUTATION ON KRAS, PIK3CA, BRAF AND NRAS GENES DETECTED WITH HIGHLY SENSITIVE TECHNIQUES: